Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.70
+1.1%
$4.90
$4.52
▼
$8.31
$65.49M0.487,792 shs3,020 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$2.53
+3.7%
$2.89
$2.09
▼
$7.82
$155.77M1.54905,125 shs728,221 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$3.12
-1.6%
$3.15
$2.43
▼
$4.83
$309.34M0.47741,051 shs501,341 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
0.00%-1.88%-1.88%-7.30%-32.08%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%+10.00%+5.42%-36.27%-52.26%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.00%-1.89%+18.18%-26.07%-19.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.70
+1.1%
$4.90
$4.52
▼
$8.31
$65.49M0.487,792 shs3,020 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$2.53
+3.7%
$2.89
$2.09
▼
$7.82
$155.77M1.54905,125 shs728,221 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$3.12
-1.6%
$3.15
$2.43
▼
$4.83
$309.34M0.47741,051 shs501,341 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
0.00%-1.88%-1.88%-7.30%-32.08%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%+10.00%+5.42%-36.27%-52.26%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.00%-1.89%+18.18%-26.07%-19.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
1.00
SellN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
2.75
Moderate Buy$26.25937.55% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.50
Moderate Buy$11.25260.58% Upside

Current Analyst Ratings Breakdown

Latest TARA, CSBR, and XFOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/3/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
10/20/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
10/15/2026
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Reiterated RatingSell (D-)
10/15/2026
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Reiterated RatingOverweight
10/2/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
UpgradeSell (E+) ➝ Sell (D)
9/16/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$59.42M1.10$0.01 per share323.45$0.29 per share16.21
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$3.80 per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$35.11M8.81N/AN/A$2.13 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$1.17M-$0.08N/AN/AN/A-1.82%-25.77%-3.71%12/15/2026 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$57.44M-$1.39N/AN/AN/AN/A-46.15%-42.75%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$79.20M-$0.67N/AN/AN/A-474.74%-49.62%-30.80%N/A

Latest TARA, CSBR, and XFOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.3657-$0.35+$0.0157-$0.35N/AN/A
11/5/2026Q3 2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$0.1680-$0.16+$0.0080-$0.16$2.78 million$2.88 million
9/10/2026Q1 2027
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$0.01$0.05+$0.06-$0.03$15.05 million$15.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
1.03
1.03
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
9.01
9.01
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.55
13.22
12.86

Institutional Ownership

CompanyInstitutional Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.30%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
7.60%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
1.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
21413.92 million7.48 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
5161.57 million56.89 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4599.15 million98.03 millionOptionable

Recent News About These Companies

Brookline Capital Markets Comments on XFOR FY2030 Earnings
4 Biotech Stocks Seeing Unusual Options Volume Today
X4 Pharmaceuticals (XFOR) Projected to Announce Earnings on Wednesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

$4.70 +0.05 (+1.08%)
Closing price 11/13/2026 03:57 PM Eastern
Extended Trading
$4.70 +0.00 (+0.11%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$2.53 +0.09 (+3.69%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.52 0.00 (-0.20%)
As of 11/13/2026 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$3.12 -0.05 (-1.58%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.12 0.00 (-0.16%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.